Ebola Clinical Trial to Begin Amid Outbreak in DRC

The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.

Nov 12, 2018
Ashley P. Taylor

ABOVE: Illustration of Ebola virus

Health officials in Democratic Republic of Congo are planning to launch a clinical trial of four Ebola treatments, STAT reports. The experimental drugs include an antiviral medicine and three monoclonal antibodies.

Rather than have a control arm, the trial will compare the efficacy of the four experimental treatments against each other, at least in Democratic Republic of Congo (DRC). Other countries that participate in the trial may choose to include a current treatment as a control arm. The drugs include the antiviral Remdesivir, and the antibodies ZMapp, REGN 3470-3471-3479, and mAB 114, which is being developed by DRC’s National Institute of Biomedical Research and the US National Institutes of Health.

The study will likely run over the course of several outbreaks in multiple countries, and it will probably begin this month, Jeremy Farrar, the head of the Wellcome Trust who is the co-chair of a group drafting the trial protocol, tells STAT.

See “Q&A: Anthony Fauci Describes an Experimental Ebola Treatment

Patients in the current outbreak, which began this summer and is the third largest Ebola outbreak on record, have been receiving these treatments for several weeks through a World Health Organization (WHO) compassionate-use protocol, STAT reports. As of Friday (November 9), 139 Ebola patients had received one of the four drugs. Although it’s unusual to use unlicensed drugs in such large quantities outside formal clinical trials, the idea was to get treatments started while health officials designed and made negotiations for the human study. 

Researchers have been collecting some data on those patients receiving the drugs, but it hasn’t been standardized, and that’s what’s needed, Annick Antierens, a strategic adviser for Médecins Sans Frontières’s medical department, tells STAT. “We need to start randomizing. We need to start generating evidence and having a harmonized way of collecting data.” Mike Ryan, deputy head of the WHO’s emergency response operation, tells STAT that he believes this compassionate-use period has been an opportunity for health workers to get familiar with administering the drugs. 

Violence in DRC makes treating Ebola patients and conducting this trial all the more difficult. “People are being shot at, and it’s not just the occasional bit of gunfire,” Farrar tells STAT, speaking of the province of North Kivu, the site of the outbreak. “There’s mortars, there’s kidnappings—it is an intensely fragile environment with a lot of conflict that’s been going on for years.”

“Everyone wants this to be a success,” Ryan tells STAT. “Everyone wants a good RCT [randomized controlled trial] to finally work out what value each of these therapies has in the treatment of Ebola. We’ve seen promising signs . . . but no one will ever know until we do a proper RCT.”

December 2018

Invisible Borders

An emerging appreciation for membraneless organelles and the liquid dynamics that shape them


Sponsored Product Updates

Rapid ELISA-Based Measurement Of Protein Phosphorylation
Rapid ELISA-Based Measurement Of Protein Phosphorylation
In this article, RayBiotech will present a study in which the phosphorylation of two proteins, STAT1 (Tyr701) and Mek1 (Ser217/221), is detected in response to various agonists. Data from the RayBio® Phosphorylation ELISA kits will be compared to traditional immunoblotting.
Protein Sample Quality Identification and Evaluation
Protein Sample Quality Identification and Evaluation
Checking the quality of your protein before and during your process gives you the highest chance of getting the consistent results. Learn how to evaluate the quality of your protein samples with this application note from NanoTemper!
Using CDD Vault to Manage Redbrick Molecular Ltd. Catalogues - A Case Study
Using CDD Vault to Manage Redbrick Molecular Ltd. Catalogues - A Case Study
Check out this case study to find out why Redbrick Molecular Ltd. chose CDD Vault as their database and informatics platform, and how they made use of the CDD Vault to implement a complex catalogue in a simple way.
New automated N-glycan profiling web app shaves days off of data interpretation for glycobiologists
New automated N-glycan profiling web app shaves days off of data interpretation for glycobiologists
The first automated, web-based application that enables routine use of enzymatic digestions to improve N-glycan analyses from New England Biolabs (NEB). This software not only saves precious times for glycobiologists who are more attuned to traditional methods, but also provides the most accurate interpretation of glycan enzymatic digestion data on the market.